Literature DB >> 23763772

Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: differential expression of neurotrophic and gliotrophic factors.

Fei Song1, Manoj Bandara, Harvinder Deol, Jeffrey A Loeb, Joyce Benjamins, Robert P Lisak.   

Abstract

Soluble factors that promote survival and differentiation of glia and neurons during development are likely to play key roles in neurodegeneration and demyelinating diseases such as multiple sclerosis (MS) and have the potential to be important therapeutic targets. We examined the effect of TrkB signaling and the expression patterns of neurotrophic and gliotrophic factors in the mouse brain in MOG-induced experimental allergic encephalomyelitis (EAE). With induction of mild disease, TrkB heterozygous mice were more severely affected compared to their wild type littermates. However, with more potent disease induction, TrkB heterozygotes fared similar to their wild type littermates, suggesting complex modulatory roles for TrkB signaling. One possible explanation for this difference is that the expression patterns of neurotrophic factors correlate with disease severity in individual mice with mild disease, but not in more severe disease. With the less potent induction in C57BL/6 mice, we found that BDNF was consistently increased at EAE onset, while the soluble gliotrophic factor neuregulin (NRG1) was increased only in the chronic phase of the disease. Treatment of these animals with glatiramer acetate (GA) to decrease disease severity resulted in lower levels of both BDNF and NRG1 expression in some mice at 35days after immunization compared to those in untreated EAE mice, but had no direct effect on these factors in the absence of EAE. Our results suggest a complex interplay between neurotrophic and gliotrophic factors in EAE that is dependent on disease stage and severity. While signaling by BDNF through TrkB is protective in mild disease, this effect was not seen in more severe disease. The late induction of NRG1 in the chronic stage of disease could also worsen disease severity through its known ability to activate microglial, inflammatory pathways. While complex, these studies begin to define underlying axoglial trophic activities that are likely involved in both disease pathogenesis and repair.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BDNF and TrkB tyrosine kinase receptor; Experimental autoimmune encephalomyelitis; Glatiramer acetate; Multiple sclerosis; Neuregulin1

Mesh:

Substances:

Year:  2013        PMID: 23763772      PMCID: PMC3769424          DOI: 10.1016/j.jneuroim.2013.05.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  48 in total

Review 1.  Neurotrophins in cell survival/death decisions.

Authors:  P Casaccia-Bonnefil; C Gu; M V Chao
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Neuregulin expression at neuromuscular synapses is modulated by synaptic activity and neurotrophic factors.

Authors:  Jeffrey A Loeb; Abdelkrim Hmadcha; Gerald D Fischbach; Susan J Land; Vaagn L Zakarian
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

Review 4.  Neurotrophins and their receptors: a convergence point for many signalling pathways.

Authors:  Moses V Chao
Journal:  Nat Rev Neurosci       Date:  2003-04       Impact factor: 34.870

5.  Neuregulin in neuron/glial interactions in the central nervous system. GGF2 diminishes autoimmune demyelination, promotes oligodendrocyte progenitor expansion, and enhances remyelination.

Authors:  M A Marchionni; B Cannella; C Hoban; Y L Gao; R Garcia-Arenas; D Lawson; E Happel; F Noel; P Tofilon; D Gwynne; C S Raine
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

6.  Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.

Authors:  S Ragheb; S Abramczyk; D Lisak; R Lisak
Journal:  Mult Scler       Date:  2001-02       Impact factor: 6.312

7.  Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis.

Authors:  Fei Song; Pohung Chiang; Jiajing Wang; John Ravits; Jeffrey A Loeb
Journal:  J Neuropathol Exp Neurol       Date:  2012-02       Impact factor: 3.685

8.  Neuregulin and erbB receptor expression in normal and diseased human white matter.

Authors:  B Cannella; D Pitt; M Marchionni; C S Raine
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

9.  BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

Authors:  Christine Stadelmann; Martin Kerschensteiner; Thomas Misgeld; Wolfgang Brück; Reinhard Hohlfeld; Hans Lassmann
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

10.  Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration.

Authors:  Emanuela Colombo; Chiara Cordiglieri; Giorgia Melli; Jia Newcombe; Markus Krumbholz; Luis F Parada; Enzo Medico; Reinhard Hohlfeld; Edgar Meinl; Cinthia Farina
Journal:  J Exp Med       Date:  2012-03-05       Impact factor: 14.307

View more
  4 in total

1.  Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.

Authors:  Jody Corey-Bloom; Haiqun Jia; Alaina M Aikin; Elizabeth A Thomas
Journal:  J Huntingtons Dis       Date:  2014

2.  Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders.

Authors:  Yu Sun; Vaibhav A Narayan; Gayle M Wittenberg
Journal:  BMC Pharmacol Toxicol       Date:  2016-10-21       Impact factor: 2.483

Review 3.  Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.

Authors:  Kim M A De Kleijn; Gerard J M Martens
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

4.  Estrogen receptor (ER) β expression in oligodendrocytes is required for attenuation of clinical disease by an ERβ ligand.

Authors:  Anna J Khalaj; Jaehee Yoon; Jaspreet Nakai; Zachary Winchester; Spencer M Moore; Timothy Yoo; Leonardo Martinez-Torres; Shalini Kumar; Noriko Itoh; Seema Kaushalya Tiwari-Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.